356 related articles for article (PubMed ID: 8853753)
1. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Hirschowitz BI; Simmons J; Mohnen J
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
5. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
7. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
[TBL] [Abstract][Full Text] [Related]
9. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
Pospaï D; Cadiot G; Forestier S; Ruszniewski P; Coste T; Escourrou J; Mignon M; Gresze
Gastroenterol Clin Biol; 1998 Oct; 22(10):801-8. PubMed ID: 9854205
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
Jensen RT; Metz DC; Koviack PD; Feigenbaum KM
Aliment Pharmacol Ther; 1993; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079
[TBL] [Abstract][Full Text] [Related]
13. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
14. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Wilcox CM; Seay T; Arcury J; Hirschowitz BI
Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392
[TBL] [Abstract][Full Text] [Related]
15. Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion.
Fich A; Talley NJ; Shorter RG; Phillips SF
Dig Dis Sci; 1991 Jan; 36(1):10-4. PubMed ID: 1984995
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori and Zollinger-Ellison syndrome.
Saeed ZA; Evans DJ; Evans DG; Cornelius MJ; Maton PN; Jensen RT; Graham DY
Dig Dis Sci; 1991 Jan; 36(1):15-8. PubMed ID: 1984998
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
18. Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
Wilcox CM; Martin T; Phadnis M; Mohnen J; Worthington J; Hirschowitz BI
BMC Gastroenterol; 2008 May; 8():18. PubMed ID: 18507843
[TBL] [Abstract][Full Text] [Related]
19. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
20. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Jensen RT; Fraker DL
JAMA; 1994 May; 271(18):1429-35. PubMed ID: 7513768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
